Related Experiment Videos
Elevated plasma neopterin levels in Alzheimer disease
M Hull1, G M Pasinetti, P S Aisen
1Department of Psychiatry, Mount Sinai Medical Center, New York, New York, USA.
Alzheimer Disease and Associated Disorders
|February 24, 2001
Summary
Plasma neopterin levels are elevated in Alzheimer disease (AD) patients, indicating increased inflammation. While not diagnostic, this finding may inform future anti-inflammatory treatments for AD.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alzheimer disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline.
- Inflammation is increasingly recognized as a significant factor in AD pathogenesis.
- Neopterin is a biomarker of immune system activation and oxidative stress.
Purpose of the Study:
- To evaluate plasma neopterin levels as a potential marker of inflammation in Alzheimer disease (AD).
- To explore the relationship between neopterin levels and clinical parameters in AD patients.
Main Methods:
- Plasma samples were collected from 51 patients diagnosed with AD and 38 age-matched healthy controls.
- Plasma neopterin concentrations were measured using a standard assay.
- Statistical analyses were performed to compare groups and assess correlations.
Main Results:
- Plasma neopterin levels were significantly higher in AD patients compared to controls (9.3 +/- 5.9 ng/mL vs. 6.3 +/- 2.6 ng/mL, p = 0.002).
- No significant correlation was found between neopterin levels and Mini-Mental State Examination scores or disease duration.
- A weak association was observed between neopterin levels and patient age (r = 0.26, p = 0.02).
Conclusions:
- Elevated plasma neopterin suggests an inflammatory component in Alzheimer disease.
- Plasma neopterin measurement is not currently useful for diagnosing AD.
- Neopterin levels may offer insights for developing novel anti-inflammatory therapeutic strategies for AD.